The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
Published version of a preprint
Abstract
Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated (single-hit) or multiple (multi-hit) TP53 aberrations remains unclear, particularly in the context of targeted agents. Patients and Methods: We performed deep sequencing of TP53 using baseline samples collected from 51 TP53 aberrant patients treated with ibrutinib in a phase II study (NCT01500733). Results: We identified TP53 mutations in 43 patients (84%) and del(17p) in 47 (92%); 9 and 42 patients carried single-hit and multi-hit TP53, respectively. The multi-hit TP53 subgroup was enriched with younger patients who had prior treatments and unmutated immunoglobulin heavy-chain variable region gene status. We observed significantly shorter overall survival, progression-free survival (PFS), and time-to-progression (TTP) in patients with multi-hit TP53 compared with those with single-hit TP53. Clinical outcomes were similar in patient subgroups stratified by 2 or >2 TP53 aberrations. In multivariable analyses, multi-hit TP53 CLL was independently associated with inferior PFS and TTP. In sensitivity analyses, excluding mutations below 1% VAF demonstrated similar outcome. Results were validated in an independent population-based cohort of 112 patients with CLL treated with ibrutinib. Conclusions: In this study, single-hit TP53 defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit TP53 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit TP53 CLL. See related commentary by Bomben et al., p. 4462
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well documented that, compared to single-hit (SH) mutations, multi-hit (MH) TP53 mutations are associated with worse prognosis and poorer outcomes in cancers compared to single-hit (SH) mutations 14, 43 with largely unknown causes.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood · doi:10.1182/blood-2016-06-719294 · Cited by 341
Self-citationDepth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Self-citationThe evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Landau, D. A., Sun, C., Rosebrock, D., Herman, S. E. M., Fein, J., Sivina, M., Underbayev, C., Liu, D., Hoellenriegel, J., Ravichandran, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02329-y · Cited by 176
Self-citation
Research works printed but not linked: 43
- Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
- Donehower, 2019, Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas, Cell Rep, 28, 3010, 10.1016/j.celrep.2019.08.061 · DOI · Paper page
- Stilgenbauer, 2014, Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial, Blood, 123, 3247, 10.1182/blood-2014-01-546150 · DOI · Paper page
- Bahlo, 2016, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, 17, 779, 10.1016/S1470-2045(16)30029-8 · DOI · Paper page
- Burger, 2020, Treatment of chronic lymphocytic leukemia, N Engl J Med, 383, 460, 10.1056/NEJMra1908213 · DOI · Paper page
- da Cunha-Bang, 2016, The Danish national chronic lymphocytic leukemia registry, Clin Epidemiol, 8, 561, 10.2147/CLEP.S99486 · doi:10.2147/clep.s99486
- Dohner, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, 343, 1910, 10.1056/NEJM200012283432602 · DOI · Paper page
- Zenz, 2012, Risk categories and refractory CLL in the era of chemoimmunotherapy, Blood, 119, 4101, 10.1182/blood-2011-11-312421 · doi:10.1182/blood-2011-11-312421
- Hallek, 2018, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, 131, 2745, 10.1182/blood-2017-09-806398 · DOI · Paper page
- Malcikova, 2018, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, Leukemia, 32, 1070, 10.1038/s41375-017-0007-7 · DOI · Paper page
- Eichhorst, 2021, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 32, 23, 10.1016/j.annonc.2020.09.019 · DOI · Paper page
- Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
- Malcikova, 2009, Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage, Blood, 114, 5307, 10.1182/blood-2009-07-234708 · DOI · Paper page
- Zenz, 2010, TP53 mutation and survival in chronic lymphocytic leukemia, J Clin Oncol, 28, 4473, 10.1200/JCO.2009.27.8762 · DOI · Paper page
- Stengel, 2017, The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS, and CLL: an analysis of 3307 cases, Leukemia, 31, 705, 10.1038/leu.2016.263 · DOI · Paper page
- Campo, 2018, TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics, Haematologica, 103, 1956, 10.3324/haematol.2018.187583 · DOI · Paper page
- Nadeu, 2016, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood, 127, 2122, 10.1182/blood-2015-07-659144 · DOI · Paper page
- DiNardo, 2020, Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML, Blood, 135, 791, 10.1182/blood.2019003988 · DOI · Paper page
- Yu, 2017, Survival of Del17p CLL depends on genomic complexity and somatic mutation, Clin Cancer Res, 23, 735, 10.1158/1078-0432.CCR-16-0594 · DOI
- Blakemore, 2020, Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial, Leukemia, 34, 1760, 10.1038/s41375-020-0723-2 · DOI
- Brieghel, 2019, Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment, Haematologica, 104, 789, 10.3324/haematol.2018.195818 · DOI
- Rossi, 2009, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness, Clin Cancer Res, 15, 995, 10.1158/1078-0432.CCR-08-1630 · DOI · Paper page
- Rossi, 2014, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, 123, 2139, 10.1182/blood-2013-11-539726 · DOI · Paper page
- Tam, 2009, De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M.D. Anderson and Mayo Clinic experience, Blood, 114, 957, 10.1182/blood-2009-03-210591 · doi:10.1182/blood-2009-03-210591
- Farooqui, 2015, Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, Lancet Oncol, 16, 169, 10.1016/S1470-2045(14)71182-9 · DOI · Paper page
- Byrd, 2019, Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs. ofatumumab, Blood, 133, 2031, 10.1182/blood-2018-08-870238 · DOI · Paper page
- O'Brien, 2018, Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience, Blood, 131, 1910, 10.1182/blood-2017-10-810044 · DOI · Paper page
- Ahn, 2020, Ibrutinib for chronic lymphocytic leukemia with TP53 alterations, N Engl J Med, 383, 498, 10.1056/NEJMc2005943 · DOI
- Aarup, 2020, Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib, Eur J Haematol, 105, 646, 10.1111/ejh.13499 · DOI
- Firth, 1993, Bias reduction of maximum likelihood estimates, Biometrika, 80, 27, 10.1093/biomet/80.1.27 · DOI · Paper page
- R Core Team, 2020, R: a language and environment for statistical computing
- O'Brien, 2018, Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials, JAMA Oncol, 4, 712, 10.1001/jamaoncol.2017.5604 · DOI
- Soumerai, 2019, Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations, Lancet Haematol, 6, e366, 10.1016/S2352-3026(19)30085-7 · DOI
- Ahn, 2021, Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model, J Clin Oncol, 39, 576, 10.1200/JCO.20.00979 · DOI
- Bieging, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat Rev Cancer, 14, 359, 10.1038/nrc3711 · DOI · Paper page
- Malcikova, 2015, Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia, Leukemia, 29, 877, 10.1038/leu.2014.297 · DOI
- Leeksma, 2021, Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study, Haematologica, 106, 87, 10.3324/haematol.2019.239947 · DOI
- European Research Initiative on CLL, Projects: Multicenter study on prognostic and predictive impact of TP53 variants below 10% VAF
- Jain, 2019, Ibrutinib and venetoclax for first-line treatment of CLL, N Engl J Med, 380, 2095, 10.1056/NEJMoa1900574 · DOI · Paper page
- Hillmen, 2019, Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study, J Clin Oncol, 37, 2722, 10.1200/JCO.19.00894 · DOI · Paper page
- Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519 · DOI · Paper page
- Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 · DOI · Paper page
- Rogers, 2020, Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia, J Clin Oncol, 38, 3626, 10.1200/JCO.20.00491 · DOI
Cited by
Integrin Signaling Shaping BTK-Inhibitor Resistance
Polcik, L., Dannewitz Prosseda, S., Pozzo, F., Zucchetto, A., Gattei, V., & Hartmann, T. N. (2022) · Cells · doi:10.3390/cells11142235 · Cited by 15
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Metadata
- Authors
- Brieghel, C., Aarup, K., Torp, M. H., Andersen, M. A., Yde, C. W., Tian, X., Wiestner, A., Ahn, I. E., & Niemann, C. U.
- Affiliations
- 1Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- 2Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- 3Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- 4Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
- Venue
- Clinical Cancer Research
- Published
- 2021-05-07
- Volume
- 27
- Issue
- 16
- Pages
- 4531-4538
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 41
- References
- 6
- Language
- en
- Funders
- Danish Cancer Society
- Intramural Research Program of the National Heart, Lung, and Blood Institute
- Novo Nordisk Foundation (NNF16OC0019302)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4890
- The paper
- Brieghel, C., Aarup, K., Torp, M. H., Andersen, M. A., Yde, C. W., Tian, X., Wiestner, A., Ahn, I. E., & Niemann, C. U. (2021). Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.